Evidence map›Paper›PMID 37176604›Full record

ArticleJournal of clinical medicine2023

Is Olfactory Testing a Useful Diagnostic Tool to Identify SARS-CoV-2 Infections Early? A Cross-Sectional and Longitudinal Analysis.

Christiana Graf, Inken Wagener, Katharina Grikscheit, Sebastian Hoehl, Annemarie Berger, Nils Wetzstein, Julia Dietz, Georg Dultz, Florian Michael, Natalie Filmann and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Christiana GrafInstitute of Medical Virology, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.
Inken WagenerInstitute of Medical Virology, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.
Katharina GrikscheitInstitute of Medical Virology, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.ORCID 0000-0003-1102-078X
Sebastian HoehlInstitute of Medical Virology, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.ORCID 0000-0002-5100-9385
Annemarie BergerInstitute of Medical Virology, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.
Nils WetzsteinDepartment of Internal Medicine II, Infectious Diseases, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.
Julia DietzDepartment of Internal Medicine I, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.
Georg DultzDepartment of Internal Medicine I, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.
Florian MichaelDepartment of Internal Medicine I, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.
Natalie FilmannInstitute of Biostatistics and Mathematical Modeling, Goethe University, 60323 Frankfurt am Main, Germany.
Eva HerrmannInstitute of Biostatistics and Mathematical Modeling, Goethe University, 60323 Frankfurt am Main, Germany.ORCID 0000-0002-0662-6675
Peter TinnemannPublic Health Department of the City of Frankfurt am Main, 60306 Frankfurt am Main, Germany.ORCID 0000-0003-3071-9772
Udo GoetschPublic Health Department of the City of Frankfurt am Main, 60306 Frankfurt am Main, Germany.
Sandra CiesekInstitute of Medical Virology, University Hospital Frankfurt, 60306 Frankfurt am Main, Germany.ORCID 0000-0002-1802-7565
Goethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGenesis and the prognostic value of olfactory dysfunction (OD) in COVID-19 remain partially described. The objective of our study was to characterize OD during SARS-CoV-2 infection and to examine whether testing of OD may be a useful tool in clinical practice in order to early identify patients with SARS-CoV-2 infection.

methodsOlfactory function assessment was objectively carried out using the u-Smell-it

resultsAmong 494 SARS-CoV-2 negative tested patients, OD was detected in 45.7% and was found to be significantly associated with the male gender (

conclusionOD is common in COVID-19 negative and positive tested patients with significantly different prevalence rates observed between different variants. Diagnostic accuracy of OD is not high enough to implement olfactory testing as a tool in diagnostic routine to early identify patients with a SARS-CoV-2 infection.

Indexed as

COVID-19 infectionsolfactory dysfunctionolfactory testSARS-CoV-2 infection

Identifiers

PMID37176604
PMCPMC10179328
OpenAlexW4367298888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.